
    
      To determine the percentage of women who achieve anemia correction after a single dose of
      1000mg of low molecular weight iron dextran(infed).

      To determine whether IV iron supplementation has a higher satisfaction with treatment as
      compared to oral supplementation in a population previously intolerant of or unresponsive to
      oral iron.

      To evaluate the safety of IV low molecular weight iron dextran in pregnant women.

      To assess maternal and fetal outcomes-preterm delivery, low birth weight deliveries, ER
      visits and hospitalizations related to preterm labor, preterm contractions, ante-partum and
      post-partum transfusions, maternal hemoglobin at post-partum visit after IV iron
      supplementation groups.
    
  